top of page




圣路易斯华盛顿大学医学院的一项GENESIS试验,分析了Motixafortide(一种CXCR4抑制剂)作为多发性骨髓瘤患者进行自体造血细胞移植前的干细胞动员活性。GENESIS试验比较motixafortide和现有的CXCR4抑制剂plerixafor [Mozobil]结果发现"更加活跃,作用时间更长"。首先它在临床前模型中的活性略高。第二它阻断的时间更长。  而且它有可能将这种CXCR4抑制剂与G-CSF[粒细胞集落刺激因子]相结合。  该药物的耐受性也非常好,只有轻微的注射部位反应。


Prior to HCT Shows Benefit in Multiple Myeloma  — CXCR4 inhibitor "dramatically synergizes the mobilization of stem cells"
John DiPersio, MD, PhD, of Washington University School of Medicine in St. Louis, discusses the analysis, which investigated motixafortide, a CXCR4 antagonist, as a mobilizing agent prior to autologous hematopoietic cell transplantation in patients with multiple myeloma.
GENESIS trial is a trial designed to study motixafortide. And this is a CXCR4 inhibitor that is slightly different than plerixafor [Mozobil].  First of all, it's slightly more active in preclinical models. Number two, it blocks for a much longer period of time. More active, longer acting.   And it has the possibility to combine this CXCR4 inhibitor with G-CSF [granulocyte colony-stimulating factor] .   The drug was also very well tolerated, with only slight injection-site reactions.

Medical Professional

Local Hospital Saves Child’s Life

bottom of page